-$139.8M
Net Activity
Institutions Holding
125
Popularity Rank
#3978
Avg Weight
0.06%
Total Value
$64.9M
125 institutions currently hold ALDX, with 68 net buyers and 69 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
69
Net Buying Institutions
68
Top 5 by Value
+$28.1M
Total Buy Value
$110.9M
Total Sell Value
68
Net Buyers
69
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Aldeyra Therapeutics received minutes from a Type A meeting with the FDA regarding the potential resubmission of its new drug application for reproxalap, a treatment for dry eye disease. The company requested clarification of those minutes and plans to request a Type D meeting, expected by the end of Q3 2026, to discuss resubmission.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter